These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo. Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990 [TBL] [Abstract][Full Text] [Related]
10. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479 [TBL] [Abstract][Full Text] [Related]
11. Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Wilson CA; di Clemente N; Ehrenfels C; Pepinsky RB; Josso N; Vigier B; Cate RL Mol Endocrinol; 1993 Feb; 7(2):247-57. PubMed ID: 8469238 [TBL] [Abstract][Full Text] [Related]
12. Insensitivity of the chick embryo müllerian duct to human recombinant müllerian-inhibiting substance. Weniger JP; Cate RL; Zeis A J Mol Endocrinol; 1992 Feb; 8(1):73-7. PubMed ID: 1543536 [TBL] [Abstract][Full Text] [Related]
13. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Ueno S; Manganaro TF; Donahoe PK Endocrinology; 1988 Sep; 123(3):1652-9. PubMed ID: 2456917 [TBL] [Abstract][Full Text] [Related]
14. A possible purification of mullerian inhibiting substance and a model for its mechanism of action. Budzik GP; Donahoe PK; Hutson JM Prog Clin Biol Res; 1985; 171():207-23. PubMed ID: 2984697 [No Abstract] [Full Text] [Related]